ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
After AdComm rejection, Mallinckrodt’s stannsoporfin gets stiff-armed at FDA
August 23, 2018The FDA has issued a complete response letter to Mallinckrodt’s jaundice drug stannsoporfin. Mallinckrodt plans to talk to the FDA in the coming months before deciding the fate of a drug it acquired in an $80 million buyout last year. -
Mallinckrodt to buy InfaCare and its paediatric jaundice treatment stannsoporfin
August 08, 2017UK-based pharmaceutical company Mallinckrodt has entered an agreement to acquire InfaCare Pharmaceutical and its developmental product, stannsoporfin, used for the treatment of newborns with the risk of developing severe jaundice.
Pharma Sources Insight January 2025
